ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Enliven Therapeutics Inc

Enliven Therapeutics Inc (ELVN)

24,54
-0,87
(-3,42%)
Geschlossen 23 November 10:00PM
24,54
0,07
(0,29%)
Nach Börsenschluss: 10:42PM

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
24,54
Gebot
23,30
Fragen
27,45
Volumen
254.134
24,36 Tagesbereich 26,09
9,80 52-Wochen-Bereich 30,03
Marktkapitalisierung
Handelsende
25,41
Handelsbeginn
25,43
Letzter Handelszeitpunkt
Finanzvolumen
US$ 6.487.465
VWAP
25,5277
Durchschnittliches Volumen (3 Mio.)
259.913
Ausgegebene Aktien
48.859.166
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-4,31
Gewinn pro Aktie (EPS)
-1,47
Erlöse
-
Nettogewinn
-71,58M

Über Enliven Therapeutics Inc

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Enliven Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELVN. The last closing price for Enliven Therapeutics was US$25,41. Over the last year, Enliven Therapeutics shares have traded in a share price range of US$ 9,80 to US$ 30,03.

Enliven Therapeutics currently has 48.859.166 shares in issue. The market capitalisation of Enliven Therapeutics is US$1,24 billion. Enliven Therapeutics has a price to earnings ratio (PE ratio) of -4.31.

ELVN Neueste Nachrichten

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire BOULDER, Colo., Nov. 13, 2024 Announced positive data from the Phase 1 clinical trial of...

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024 BOULDER, Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.435-1.7417417417424.97526.4823.719322625.20385716CS
4-4.82-16.41689373329.3629.78523.724008027.32821966CS
122.3310.490769923522.2130.0321.3425991326.03204375CS
261.657.2083879423322.8930.0319.5525401624.46485174CS
5213.37119.6956132511.1730.039.825027621.40820006CS
1560.341.4049586776924.230.039.820681820.64450046CS
2600.341.4049586776924.230.039.820681820.64450046CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PDYNPalladyne AI Corporation
US$ 4,59
(129,50%)
83M
QMCOQuantum Corporation
US$ 9,11
(126,62%)
39,41M
NANano Labs Ltd
US$ 8,26
(89,02%)
2,03M
XCURExicure Inc
US$ 18,60
(71,27%)
4,36M
SKKSKK Holdings Limited
US$ 1,75
(59,09%)
95,06M
AMIXAutonomix Medical Inc
US$ 6,21
(-54,07%)
946,09k
CETXCemtrex Inc
US$ 0,1146
(-41,74%)
24,39M
MSWMing Shing Group Holdings Ltd
 5,90
(-35,52%)
417,08k
RMSGReal Messenger Corporation
US$ 3,09
(-26,25%)
313,51k
ENSCEnsysce Biosciences Inc
US$ 0,4414
(-25,49%)
4M
ELABElevai Labs Inc
US$ 0,0201
(-0,50%)
425,38M
NVDANVIDIA Corporation
US$ 141,95
(-3,22%)
236,51M
SMCISuper Micro Computer Inc
US$ 33,15
(11,62%)
159,61M
VRPXVirpax Pharmaceuticals Inc
US$ 0,5501
(-6,72%)
159,39M
SOUNSoundHound AI Inc
US$ 8,24
(18,05%)
107,91M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock